Category: W.L. Gore & Associates
Gore Medical receives CE Mark approval in the European Union for its Viabahn vascular device for the treatment of obstructed peripheral veins in hemodialysis patients.
Gore Medical said it received CE Mark approval for its Viabahn vascular device for the treatment of obstructed peripheral veins in hemodialysis patients.
The Flagstaff, Ariz.-based company said the approval covers the treatment of obstructed peripheral veins, excluding the venae cavae and pulmonary veins.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA guides on custom devices; FDA approves Gore's Viabahn for peripheral stent repair; Alcon wins date with FDA panel for AcrySof lens; FDA seeks public input on medtech hacking; ReFlow Medical wins CE Mark for crossing catheters;
The FDA adds an indication to its approval of W.L. Gore's Viabahn peripheral stent graft in treating failed bare-metal stents.
W.L. Gore & Assoc. said the FDA granted pre-market approval for a new indication for its Viabahn endoprosthesis, to treat failed bare-metal stents in the peripheral vasculature.
Here's a look at some of the top legal news stories for medical device companies this week: Appeals court upholds Gore win over St. Jude Medical; Independent legal panel rejects Infuse allegations in Medtronic shareholder suits; Judge dismisses Anulex from Xclose off-label lawsuit; Appeals court upholds Abiomed win in shareholder's class action; Convicted ex-Heart Tronics CEO won't get a retrial, judge rules.
A federal appeals court upholds W.L. Gore & Assoc.'s win over St. Jude Medical in their patent spat over heart defect repair technology.
A federal appeals court today upheld a win for W.L. Gore & Assoc. in a patent war with St. Jude Medical (NYSE:STJ) over heart defect repair technology.
W.L. Gore's newly approved drug-coated Viabahn stent graft beat the current standard of care in treating patients with stenoses or thrombotic occlusions, according to the REVISE clinical study findings.
Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.
C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.
A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.